The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease

Zhang, Chi; Zheng, Xiaoyao; Xu, Wenrong; Shao, Xia; Li, Qingfeng; Zhang, Zheming; Zhang, Qizhi

doi:10.1016/j.jconrel.2014.07.050

Cited by 83 publications

(40 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluorescence signal in cortex was much lower than that of the other three regions, which indicated that FT mixed micelles for brain delivery may decrease the CNS side effect of drugs when other three regions were main treatment targets 36 . The results also suggested an immense possibility that the FT mixed micelles transport in brain may be greatly increased in caudate, hippocampus and substantia nigra, which showed as a potential nanocarrier for treatment of CNS diseases, such as epilepsy or Alzheimer’s disease 13, 23 .…”

Section: Discussionmentioning

confidence: 90%

“…The brain delivery of β-Gal as an enzymatic model drug incorporated in nanocarriers (F127 and FT mixed micelles) after intravenous administration in rats was assayed to evaluate the brain targeted efficacy of the carriers 23 . To determine whether the β-Gal delivered to the brain, the sections from rats brains were stained after 2 h i.v.…”

Section: Resultsmentioning

confidence: 99%

“…The treatment of CNS diseases such as brain cancers, epilepsy, CNS infection, Alzheimer’s and Parkinson’s diseases are confronted with big challenge due to the presence of BBB, which is a formidable obstacle for the delivery of most drugs to the brain 2, 23 . With the development of nanoparticles as brain-targeting delivery systems, certain drugs have been able to be transported directly into CNS, demonstrating the feasibility of the drug delivery to the brain using nano-based carriers 23, 24 .…”

Section: Discussionmentioning

confidence: 99%

“…With the development of nanoparticles as brain-targeting delivery systems, certain drugs have been able to be transported directly into CNS, demonstrating the feasibility of the drug delivery to the brain using nano-based carriers 23, 24 . In this study, we report that Pluronic F127 and TPGS mixed micelles (FT) incorporating both small-molecule (Rho123) and macromolecule (β-Gal) model drugs can be readily prepared, which could efficiently enhance the brain penetration of these model drugs.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Pluronic F127 and D-α-Tocopheryl Polyethylene Glycol Succinate (TPGS) Mixed Micelles for Targeting Drug Delivery across The Blood Brain Barrier

Meng

Liu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

A novel polymeric mixed micelle composed of Pluronic F127 and D-α-tocopheryl polyethylene glycol succinate (TPGS) was developed to improve the delivery of fluorescent dyes and protein across the blood brain barrier (BBB). Rhodamine 123 (Rho123) and DiR loaded mixed micelles, composed of Pluronic F127 and TPGS with proportion of 4:1 (FT), were prepared by thin-film hydration, and β-galactosidase (β-Gal) loaded FT mixed micelles were prepared by self-assembly. The brain-targeted capability of FT mixed micelles were evaluated both in vitro and in vivo. The FT mixed micelles showed that a average particle size of 20.03 nm, and a low CMC of 0.0031% in water. The in vitro release of Rho123 from Rho123 loaded FT mixed micelles (FT/Rho123) presented a sustained-release property. FT/Rho123 also showed higher efficiency for the accumulation in brain capillary endothelial cells (BCECs) and brain tissues. β-Gal, a model protein, was also delivered and accumulated efficiently in the brain by spontaneous loading in the FT mixed micelles. Therefore, the results indicated that F127/TPGS mixed micelles may be considered as an effective nanocarrier for the brain-targeted delivery of diagnostic and therapeutic drugs.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pluronic F127 and D-α-Tocopheryl Polyethylene Glycol Succinate (TPGS) Mixed Micelles for Targeting Drug Delivery across The Blood Brain Barrier

Meng

Liu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…chelates. More recently, a dualfunctional nanoparticle loaded with H102 peptide, a bsheet breaker peptide, was developed to specifically target Alzheimer's disease (AD) brain lesions [113]. The nanocomplex comprises of a PEG-PLA complex modified with a brain-targeting peptide, named TGN, and a peptide with increased affinity for Ab42 peptide, named QSH.…”

Section: Nanoparticles For Targeted Delivery To the Brainmentioning

confidence: 99%

Nanoparticle-Mediated Delivery of Therapeutic Drugs

Ponnappan

Chugh

2015

Pharm Med

View full text Add to dashboard Cite

Nanotechnology-based pharmaceutics is a fast emerging field in the diagnosis and therapy of a number of human diseases, including cancer. Nanoparticles offer a stable means to achieve targeted drug delivery to various cells and tissues. They have been investigated for drug delivery to different tumor tissues, to brain where the blood-brain barrier poses a significant problem in the delivery of effective therapeutic molecules, to ocular tissues and also for eliciting immune response via delivery of vaccines. Particularly, the small size of nanoparticles facilitates their easy access to a wide range of cells and tissues. Further, the size of nanoparticles can be controlled and their surface can be modified with desired ligands and receptors to specifically target cells of interest as well as achieve controlled drug release. Research is being carried out on numerous biological and synthetic nanoparticles. Diverse strategies are being developed to improve their stability, specificity and drug delivery efficiency. Nanoparticles have been also used in conjunction with cellpenetrating peptides for efficient drug delivery. Cellpenetrating peptides serve as efficient nanocarriers owing to their inherent ability to cross the plasma membrane barrier and deliver cargo to intracellular targets. Modification of nanoparticles with cell-penetrating peptides further increases their efficacy for increased permeation into varied cells and tissues. The current review focuses on different classes of nanoparticles and their application in the treatment of several types of diseases. Key PointsNanoparticle-based therapeutic drugs are widely used for the treatment of a number of diseases, including cancer.Ease of modulation of size and tuning of the nanoparticles with various ligands make them effective for formulation into specific drugs with increased therapeutic index and reduced toxicity.Successful pre-clinical and early phase clinical trials have promised the emergence of nanocarrier-based drugs.

show abstract

PEGylated β‐Sheet Breaker Peptides as Inhibitors of β‐Amyloid Fibrillization

et al. 2016

View full text Add to dashboard Cite

Three PEGylated β-sheet breaker peptides are designed as new inhibitors of β-amyloid fibrillization. The peptide Ac-Leu–Pro–Phe–Phe–Asp-NH2, considered the lead compound, and hexamers in which taurine and β-alanine substitute the acetyl group, are conjugated to poly(ethylene glycol); this conjugates self-assemble into nanoparticles. The activity of the PEGylated peptides as inhibitors of amyloid fibrillization are tested in vitro using circular dichroism spectroscopy and scanning electron microscopy. The experimental results indicate that PEGylation does not impair the ability of the β-sheet breaker peptides to inhibit fibrillogenesis in vitro. Moreover, microscopy images of β-amyloid incubated for 6 days with the taurine-containing peptide, suggest that this conjugate has major anti-fibrillogenesis activity and demonstrate the important role of the sulfonamide function against the amyloid aggregation

show abstract

The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease

Cited by 83 publications

References 33 publications

Pluronic F127 and D-α-Tocopheryl Polyethylene Glycol Succinate (TPGS) Mixed Micelles for Targeting Drug Delivery across The Blood Brain Barrier

Pluronic F127 and D-α-Tocopheryl Polyethylene Glycol Succinate (TPGS) Mixed Micelles for Targeting Drug Delivery across The Blood Brain Barrier

Nanoparticle-Mediated Delivery of Therapeutic Drugs

PEGylated β‐Sheet Breaker Peptides as Inhibitors of β‐Amyloid Fibrillization

Contact Info

Product

Resources

About